NGM·Healthcare·$869M·#60 / 520 in Healthcare
TBPH Theravance Biopharma, Inc.
70SOLID
CATEGORY BREAKDOWN
GROWTH87
QUALITY40
STABILITY96
VALUATION55
GOVERNANCE53
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+66.9%
87
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
14.4%
88
< 25% strong
Price / Sales
Market cap relative to trailing revenue
8.1x
55
< 3x strong
Rule of 40
Growth rate plus operating margin
64
100
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.7%
38
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+3.0%
82
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE TBPH WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when TBPH's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.